Clinical trial
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young…
NCT00360854 · Children's Cancer and Leukaemia Group, Other · Unknown status
Key facts
| NCT number | NCT00360854 |
|---|---|
| Title | Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma |
| Official title | Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Genetic, Other, Radiation |
| Interventions | erlotinib hydrochloride, mutation analysis, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy |
| Enrollment | 48 |
| Start date | May 1, 2005 |
| First posted | Aug 7, 2006 |
| Last update posted | Sep 20, 2013 |
| Countries | Ireland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: